Literature DB >> 17468361

Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis.

Giovanni Targher, Lorenzo Bertolini, Luca Scala, Luciano Zenari, Giuseppe Lippi, Massimo Franchini, Guido Arcaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17468361     DOI： 10.2337/dc07-0109

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  21 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

2.  Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α.

Authors:  Masihur Rehman Ajmal; Monika Yaccha; Mohammed Azharuddin Malik; M U Rabbani; Ibne Ahmad; Najmul Isalm; Nasar Abdali
Journal:  Indian Heart J       Date:  2014-08-28

Review 3.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

Review 4.  Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.

Authors:  Fabiana de Faria Ghetti; Daiane Gonçalves Oliveira; Juliano Machado de Oliveira; Lincoln Eduardo Villela Vieira de Castro Ferreira; Dionéia Evangelista Cesar; Ana Paula Boroni Moreira
Journal:  Eur J Nutr       Date:  2017-09-05       Impact factor: 5.614

5.  Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Authors:  Veeral Ajmera; Emily R Perito; Nathan M Bass; Norah A Terrault; Katherine P Yates; Ryan Gill; Rohit Loomba; Anna Mae Diehl; Bradley E Aouizerat
Journal:  Hepatology       Date:  2016-10-12       Impact factor: 17.425

6.  Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.

Authors:  Dipanjan Chanda; Chul Ho Lee; Yong-Hoon Kim; Jung-Ran Noh; Don-Kyu Kim; Ji-Hoon Park; Jung Hwan Hwang; Mi-Ran Lee; Kyeong-Hoon Jeong; In-Kyu Lee; Gi Ryang Kweon; Minho Shong; Goo-Taeg Oh; John Y L Chiang; Hueng-Sik Choi
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

7.  Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Michel Chonchol; Lorenzo Bertolini; Stefano Rodella; Luciano Zenari; Giuseppe Lippi; Massimo Franchini; Giacomo Zoppini; Michele Muggeo
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

8.  The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.

Authors:  Naim Alkhouri; Tarek Abu-Rajab Tamimi; Lisa Yerian; Rocio Lopez; Nizar N Zein; Ariel E Feldstein
Journal:  Dig Dis Sci       Date:  2009-12-05       Impact factor: 3.199

9.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients.

Authors:  G Targher; L Bertolini; S Rodella; G Zoppini; G Lippi; C Day; M Muggeo
Journal:  Diabetologia       Date:  2007-12-06       Impact factor: 10.122

10.  Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA.

Authors:  Patrick T Campbell; Lisa B VanWagner; Laura A Colangelo; Cora E Lewis; Anne Henkel; Veeral H Ajmera; Donald M Lloyd-Jones; Douglas E Vaughan; Sadiya S Khan
Journal:  Liver Int       Date:  2020-03-11       Impact factor: 5.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.